![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, April 14, 2017 3:08:47 PM
Neurotrope Aims For Alzheimer's While Brigatinib Comes Late To The Alk Party
Apr. 14, 2017 1:44 PM ET| About: Neurotrope, Inc. (NTRP), TKPPY, Includes: BMY, RHHBY
EP Vantage
Newsletter provider, biotech, healthcare
EP Vantage
(3,321 followers)
Summary
Phase II data are expected this month from Neurotrope's Alzheimer's project Bryostatin-1.
The company will need to raise more cash in the not too distant future. As of March it had approximately $24.1m, sufficient to fund operations for the next 18 to 24 months.
Meanwhile, Takeda's Alk inhibitor brigatinib will go before US regulators by April 28 in second-line NSCLC.
Welcome to your weekly digest of approaching regulatory and clinical readouts. Phase II data are expected this month from Neurotrope's (NASDAQ:NTRP) Alzheimer's project Bryostatin-1, which aims to activate protein kinase-c, though the litany of failures targeting this tricky disease is hard to ignore.
Meanwhile, Takeda's (OTCQX:TKPPY) Alk inhibitor brigatinib will go before US regulators by April 28 in second-line NSCLC. This asset came through Takeda's acquisition of Ariad, and if approved it will be entering a crowded market: only this week Roche's (OTCQX:RHHBY) competing asset Alecensa proved itself in a first-line setting, reinforcing it as the one to beat.
PKC activation
Bryostatin-1's phase IIb study tests 20 or 40 micrograms administered intravenously over 45 minutes every other week after two initial loading doses in 148 patients with moderate to severe Alzheimer's, versus placebo.
Primary endpoints measure adverse events and change from baseline in the severe impairment battery, which assesses cognition, while secondary endpoints include activities of daily living, neuropsychiatric inventory and mini-mental state exam. Topline efficacy data are due this month.
Bryostatin-1 is a protein kinase-c-epsilon activator said to target multiple pathways, including activating synaptic growth factors and amyloid-beta degrading enzymes. A phase IIa study in nine patients with mild dementia showed good tolerability, and while there was no improvement in cognition Neurotrope said only a single dose was given and that previous animal studies showed improvement with multiple doses.
Three patients also have been treated in a compassionate-use program where the company has reported improvements in cognition and daily living, and even states the possibility of disease reversal, but obviously this will need to be proven in upcoming trials.
Neurotrope was formed in 2012 out of the Blanchette Rockefeller Institute. It was originally listed on the OTC bulletin board, but last month began trading on Nasdaq after a 1-for-32 stock consolidation, since which shares are up 161% and the market cap now sits at $137m.
The company will need to raise more cash in the not too distant future. As of March it had approximately $24.1m, sufficient to fund operations for the next 18 to 24 months. Funds will be used to complete a phase II study and start an open-label extension trial and a study in Fragile X syndrome.
Bryostatin is purified from Bugula neritina, a marine invertebrate first isolated in the 1960s. It was initially tested in oncology by the NCI, but proved ineffective. The private company Aphios also is investigating it pre-clinically in Alzheimer's with APH-0703 and its analogue APH-1104.
Numerous competitor failures have turned Alzheimer's into a development graveyard, but this has not stopped investment. Biogen (NASDAQ:BIIB) just paid $300m up front for Bristol-Myers Squibb's (NYSE:BMY) phase I anti-tau MAb BMS-986168, for instance.
Late runner
Takeda's brigatinib is filed for metastatic Alk-positive NSCLC patients resistant to or intolerant of Pfizer's Xalkori and has a PDUFA date set for April 28.
The market is getting increasingly crowded with the likes of Xalkori, Zykadia and Alecensa all competing for a small patient population - only 3-5% of NSCLC cases are Alk-driven. Roche reported topline data this week showing Alecensa beating Xalkori in the first-line setting, highlighting Alecensa's potential to become the best seller in this class.
Brigatinib was one of the main drivers of Takeda's move on Ariad, and it must show that it can compete with Alecensa to justify the $5.2bn price tag. Results from brigatinib's first-line trial Alta-1L are likely to emerge towards the end of 2018, while a study in Alecensa failures started last month (Therapy focus - Roche looks ready to rule another cancer niche, March 6, 2017).
Project
Trial ID
Details
Bryostatin-1
NCT02431468
Phase IIb, 148 patients with moderate to severe Alzheimer's
Bryostatin-1
NCT02221947
Phase IIa, 9 patients with mild Alzheimer's
Brigatinib
NCT02737501
Alta-1L, brigatinib versus Xalkori in first line use, primary completion April 2019
Brigatinib
NCT02706626
After treatment with 2nd generation Alk inhibitors, primary completion June 2018
Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.
https://seekingalpha.com/article/4062492-neurotrope-aims-alzheimers-brigatinib-comes-late-alk-party?app=1&auth_param=l0ob:1cf22j9:64a92f1777b1d50aa73b856b96b7875a
Recent SNPX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:03:21 PM
- Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery • PR Newswire (US) • 05/07/2024 01:00:00 PM
- Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • PR Newswire (US) • 04/24/2024 01:15:00 PM
- Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics • PR Newswire (US) • 04/09/2024 01:15:00 PM
- Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing • PR Newswire (US) • 04/03/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:16:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:00:18 PM
- Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders • PR Newswire (US) • 12/19/2023 02:00:00 PM
- Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's • PR Newswire (US) • 12/06/2023 02:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/14/2023 10:05:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/13/2023 10:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 10:00:23 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/03/2023 09:00:19 PM
- Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology • PR Newswire (US) • 11/02/2023 01:00:00 PM
- Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease • PR Newswire (US) • 09/26/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 08:05:55 PM
- Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study • PR Newswire (US) • 09/07/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:00:40 PM
- Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis • PR Newswire (US) • 07/19/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2023 12:55:57 PM
- Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience • PR Newswire (US) • 07/13/2023 01:00:00 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM